![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 60.50 | 60.00 | 61.00 | 60.50 | 60.50 | 60.50 | 14,770 | 07:44:37 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -2.77 | 8.07M |
Date | Subject | Author | Discuss |
---|---|---|---|
30/10/2019 09:59 | I suppose it's good to have twitter fans Ged and the reports are interesting after all. | ![]() lr2 | |
30/10/2019 09:26 | NHS pagers are leaking medical data Unprotected pager messages are broadcasting health and medical data across UK cities | ![]() lr2 | |
30/10/2019 09:20 | Artificial Intelligence: How to get it right | ![]() lr2 | |
30/10/2019 08:09 | goes lower | ![]() sammyshares | |
29/10/2019 21:10 | Strange sonie01 isn’t it? A mcap of around £20m+ doesn’t seem extravagant for the IP of Cadran, TexRAD and Bleepa so why is the share price languishing at 1-1.3p? Simple case of lack of traction imo, the BOD just seem unable to work the market and if nobody knows what they are doing why should they invest? As scientists I am sure they are brilliant, the products Iam confident are excellent BUT as businessmen they have yet to prove they have a clue. Let us hope they learn soon. | ![]() bobd29 | |
29/10/2019 17:37 | Honestly? I thought this should be at the 4-5p range by now waiting for news on contracts etc, it seems to have lost traction and the 'feel good' factor about it | sonie01 | |
29/10/2019 17:31 | We all know where this is going. | ![]() sammyshares | |
29/10/2019 15:50 | Certainly a slight worry what with the BOD previous track record | sonie01 | |
29/10/2019 15:36 | "Significant growth"??? There have been a few too many pork pies LR2. | ![]() ducatiman | |
29/10/2019 14:57 | That would be handy considering the reduction in Sales & Distribution staff. | ![]() lr2 | |
29/10/2019 14:49 | I am rather hoping that Bleepa will sell itself! | ![]() ducatiman | |
29/10/2019 14:39 | I think there's a possible risk of (especially) clinicians asking "can it do this as well ?" type questions. So assuming BleepA is a real step up from what exists already, FDBK need to present it as a finished product. I learnt that the hard way years ago - you can get caught up in making 'improvements' when the original thing was absolutely fine as it was and would have been bought in its original state. From a sales point of view its too easy to try to please a potential buyer with a "we'll look into that and come back to you", rather than just asking the possibly painful question "how many do you want ?". That always tells you way more than anything else, whether the outcome is positive or negative. Perhaps you'd lose 10% of the buyers who want some additions or changes, but if the other 90% are OK with it, there's no point. Often the 10% were never going to be buyers anyway. Hopefully FDBK have some hard-nosed sales people. | ![]() yump | |
29/10/2019 09:13 | Technically it may well come under the medical device label - I just meant it wont have to undergo the patient testing / verification / write a load of papers for peer review etc as its a utility. Well I hope not - that would be a sad reflection of our NHS. Record here is I agree pretty poor is why stayed clear before. Its just gone into my punty portfolio as it passed the simple product test. | ![]() yump | |
29/10/2019 00:27 | Yump , Greetings ,I Respect your posts they are unbiased with an in depth knowledge of the sector via experience and are highly credible ,Appreciate your contribution So to try and answer I may be proved totally wrong, but whatever the share price is doing, BleepA is not a medical device really, which imo gives it a fighting chance. When Bleepa was first announced we were lead to believe it was under the Cadran umbrella as an offshoot from Cadran ( This after MONTHS of Preparation ) and therefor did not constitute the need for CE , However it has now come to light ( from our not so qualified Radiologist ) that actually BLeepa does Need a CE Mark ,So I assume the reason being its classed as a Medical Devise Pre Placing there was a lot of rhetoric coming out of Bourn regards the NHS contacts that TO & RS held within the NHS and a lot of credence was given to this by all LTH & New as it seemed very logic given there background + The added spearhead Motto " The future of NHS Communication " led a lot of us to assume ( in July ) that " Oh Yes ! At last we have turned a corner with a New, Dynamic Attentive,Young CEO at the helm who has unearthed this nailed on multi universal app and will deliver straight into the NHS heartland as no CE needed just a PLug and Play with contracts more or less secure OK , I concede those actual words were not up on a Billboard but that was definitely the rhetoric coming out from Feedback plc and we know this is AIM so it just has to be a nailed on Cert right !!!! FFWD to end October / November and LTH are coming terms with the realization of yet another Gimmick to keep the lights On , I can tell you a lot are perplexed at recent turn of events | ![]() botak54 | |
28/10/2019 22:47 | Again some good points raised, Yump. You're very new to this share. I'm new. But there are many who have stayed with this company for many years. I can see what they are concerned about. The good about this company is that there is such a great deal of potential with the products and the associated companies. That's what seduced me! The bad is the failed promises. Look at October 2018 RNS Use of Proceeds: · Expansion of the Company's sales and marketing services · Development of technical product support for the new Cadran product offerings and to expand the Cadran customer base · To fund regulatory consultant commission costs in relation to the Company's plans to secure regulatory approval of TexRAD® with the US FDA, including 510k as a medical device and CFR Chapter 21 part 11 compliance for use in clinical trials of drug candidates for FDA marketing approval · To develop the Company's partnership with Imaging Endpoints, its US imaging company partner, in order to maximise its sales in the US · To facilitate new staff appointments Now read the Annual Report. Where are any of these things mentioned? No.2 maybe but nothing else. Raising money under false pretence? Fraud? I and am sure others have repeatedly asked about FDA clearance for TexRAD. Yet no answer. And where was the Invoiced Sales figure which for so long has been shouted about. I'm very concerned. Please give me some inspiration! | ![]() ged5 | |
28/10/2019 22:28 | I didn't! He used lower case g! :-) | ![]() ged5 | |
28/10/2019 17:39 | Always liked Elvis Perkins myself. | ![]() lr2 | |
28/10/2019 17:37 | Managed a sub 1.05p top up myself today, amazing what impatience and bargains can be thrown up in this market atm | ![]() dave4545 | |
28/10/2019 17:14 | Was it travis Perkins or Perkins travis though? Pop culture reference for the oldies | ![]() coldspring | |
28/10/2019 17:04 | He may have said 'Timber' but I thought 'Plank' and then I filtered him. | ![]() lr2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions